| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10335452 | MALLINCKRODT IRELAND | Method of treating patients with hepatorenal syndrome type 1 |
Apr, 2037
(12 years from now) | |
Terlivaz is owned by Mallinckrodt Ireland.
Terlivaz contains Terlipressin Acetate.
Terlivaz has a total of 1 drug patent out of which 0 drug patents have expired.
Terlivaz was authorised for market use on 14 September, 2022.
Terlivaz is available in powder;intravenous dosage forms.
Terlivaz can be used as a method to improve kidney function in adults with hepatorenal syndrome with rapid reduction in kidney function.
Drug patent challenges can be filed against Terlivaz from 14 September, 2026.
The generics of Terlivaz are possible to be released after 05 April, 2037.
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Sep 14, 2027 |
| Orphan Drug Exclusivity(ODE-406) | Sep 14, 2029 |
Drugs and Companies using TERLIPRESSIN ACETATE ingredient
NCE-1 date: 14 September, 2026
Market Authorisation Date: 14 September, 2022
Treatment: A method to improve kidney function in adults with hepatorenal syndrome with rapid reduction in kidney function
Dosage: POWDER;INTRAVENOUS
TERLIVAZ family patents
